Valuation: Geron Corporation

Market Cap 905M 793M 737M 676M 1.27B 87.34B 1.29B 8.77B 3.43B 42.7B 3.4B 3.32B 148B P/E 2026 *
-70.5x
P/E 2027 * 22.3x
Enterprise Value 884M 774M 720M 661M 1.24B 85.31B 1.26B 8.57B 3.35B 41.71B 3.32B 3.25B 144B EV / Sales 2026 *
3.78x
EV / Sales 2027 * 2.21x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week+2.17%
Current month+10.16%
1 month+11.90%
3 months-6.00%
6 months+5.22%
Current year+6.82%
1 week 1.4
Extreme 1.4
1.49
1 month 1.26
Extreme 1.26
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%+2.17%+14.63%-54.07% 924M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%+1.58%-15.68%-15.43% 23.35B
-1.82%-3.15%+3.76%+405.88% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.42%+24.22%+179.23% 14.11B
Average -0.24%+0.23%+41.56%+151.31% 24B
Weighted average by Cap. -0.18%-0.22%+44.04%+135.36%

Financials

2026 *2027 *
Net sales 234M 205M 190M 175M 329M 22.58B 335M 2.27B 886M 11.04B 878M 859M 38.14B 333M 292M 271M 249M 469M 32.17B 477M 3.23B 1.26B 15.73B 1.25B 1.22B 54.33B
Net income -13.87M -12.16M -11.29M -10.37M -19.54M -1.34B -19.84M -134M -52.58M -655M -52.07M -50.94M -2.26B 46.53M 40.78M 37.89M 34.79M 65.55M 4.49B 66.57M 451M 176M 2.2B 175M 171M 7.59B
Net Debt -20.97M -18.38M -17.08M -15.68M -29.54M -2.02B -30M -203M -79.49M -990M -78.71M -77.01M -3.42B -169M -148M -138M -126M -238M -16.32B -242M -1.64B -641M -7.98B -634M -621M -27.56B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-07-22 US$1.410 -2.08% 5,671,002
26-07-21 US$1.440 0.00% 5,143,963
26-07-20 US$1.440 0.00% 5,209,660
26-07-17 US$1.440 +1.41% 4,784,000
26-07-16 US$1.420 0.00% 6,800,693
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.410USD
Average target price
3.400USD
Spread / Average Target
+141.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock